HLB (028300) surged from the opening of the session on the back of positive news related to its novel liver cancer drug, triggering consecutive volatility halts (VI).

As of 9:01 a.m. on the 16th, HLB was trading at 40,450 won, up more than 15% from the previous trading day, successfully recovering the 40,000 won level. This came after the company stated the previous day that most issues related to U.S. approval of its liver cancer drug had been resolved, followed by strong buying interest flowing in from the morning.

In fact, HLB triggered a VI at 9:00 a.m., immediately after the regular market opened. Moreover, even in the pre-market non-listed stock trading market (NXT), VIs were triggered multiple times in succession at 8:00 a.m., 8:02 a.m., and 8:04 a.m., demonstrating explosive demand.

In the stock market, keen attention is being focused on whether HLB will see further gains during the session and whether additional VIs will be triggered, as the company reclaimed the 40,000 won level on the back of overwhelming demand even before the market opened. However, given that the stock price has fluctuated sharply in recent times, a cautious approach is required to prepare for volatility.

At the same time, the two major domestic stock indices are showing a downward trend. KOSPI is down more than 4%, and KOSDAQ is down more than 2%.

[※ This article is for reference in making investment decisions, and the final responsibility for investments lies with the investor.]